Gravity Branding names Novartis’ Vijoice® (alpelisib)
SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gravity Branding, the agency behind naming blockbuster drugs including Novartis Kisqali (ribociclib), Genentechs Herceptin (trastuzumab) and Janssens Concerta (methylphenidate HCl), recently announced its success naming Vijoice (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).
- SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gravity Branding, the agency behind naming blockbuster drugs including Novartis Kisqali (ribociclib), Genentechs Herceptin (trastuzumab) and Janssens Concerta (methylphenidate HCl), recently announced its success naming Vijoice (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).
- Weve enjoyed a highly collaborative, productive working relationship with the Novartis team over many years on a wide range of projects, said Edward Saenz, Managing Director, Gravity Branding.
- For naming Vijoice, as with other initiatives, we employed our proven Brand Bullseye process, which helps teams align around a singular expression of brand value.
- In addition to Gravitys pharmaceutical naming experience, the agency works alongside Novartis and its technology partners on branding ground-breaking digital therapeutics.